TOP TEN perturbations for 28893 (Homo sapiens)

Organism: Homo sapiens
Gene: 28893
Selected probe(set): 215176_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 28893 (215176_x_at) across 5392 perturbations tested by GENEVESTIGATOR:

osteoarthritis study 4 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-6.474659
Number of Samples:5 / 6
Experimental osteoarthritis study 4
Synovial tissue biopsy from a swollen knee of patients with osteoarthritis (active disease). Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

rheumatoid arthritis study 1 / normal synovial membrane tissue

Relative Expression (log2-ratio):6.3843937
Number of Samples:5 / 6
Experimental rheumatoid arthritis study 1
Synovial membrane tissue from patients with rheumatoid arthritis.
Control normal synovial membrane tissue
Normal synovial membrane tissue.

multiple sclerosis study 10 (PP-MS) / cerebrospinal fluid cell sample (mixed neuropathologies)

Relative Expression (log2-ratio):5.905052
Number of Samples:10 / 9
Experimental multiple sclerosis study 10 (PP-MS)
Cerebrospinal fluid (CSF) cell samples from patients with primary progressive multiple sclerosis (PP-MS). Active disease was defined by the presence of any of the following criteria during 6 month prior CSF collection: (1) one or more relapses, (2) change of 0.5 point or greater in EDSS (Expanded Disability Status Score), (3) change in the number and size of lesions visualized by gadolinium-enhanced MRI. Untreated MS patients did not receive any medication for at least 1 year before CSF sample collection.
Control cerebrospinal fluid cell sample (mixed neuropathologies)
Cerebrospinal fluid (CSF) cell samples from patients with different neuropathologies, other than multiple sclerosis.

MEDI-551 study 3 (10 mg/kg) / scleroderma study 4 (placebo; 85d)

Relative Expression (log2-ratio):-5.8154545
Number of Samples:6 / 4
Experimental MEDI-551 study 3 (10 mg/kg)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous injection of MEDI-551 (10 mg/kg), an anti-CD19 monoclonal antibody. ATC code:---
Control scleroderma study 4 (placebo; 85d)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous placebo treatment. ATC code:---

inclusion body myositis study 1 / normal biceps tissue

Relative Expression (log2-ratio):5.7922955
Number of Samples:5 / 3
Experimental inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal biceps tissue
Biceps femoris biopsy muscle samples from control subjects.

MEDI-551 study 3 (3 mg/kg) / scleroderma study 4 (placebo; 85d)

Relative Expression (log2-ratio):-5.559864
Number of Samples:3 / 4
Experimental MEDI-551 study 3 (3 mg/kg)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous injection of MEDI-551 (3 mg/kg), an anti-CD19 monoclonal antibody. ATC code:---
Control scleroderma study 4 (placebo; 85d)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous placebo treatment. ATC code:---

microcrystalline arthritis study 1 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-5.4189043
Number of Samples:4 / 6
Experimental microcrystalline arthritis study 1
Synovial tissue biopsy from a swollen knee of patients with microcristalline arthritis (active disease). The diagnosis of microcrystalline arthritis was based on the identification of urate or calcium pyrophosphate crystals in the synovial fluid. Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; liver)

Relative Expression (log2-ratio):5.415368
Number of Samples:7 / 3
Experimental breast cancer study 42 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma.
Control breast cancer study 42 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary breast adenocarcinoma.

HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)

Relative Expression (log2-ratio):-5.3405237
Number of Samples:5 / 4
Experimental HCV-related HCC study 1
Hepatitis C infection related human hepatocellular carcinoma sample.
Control adjacent HCV-related liver tissue (LC)
Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis.

necrotizing myopathy study 1 / inclusion body myositis study 1

Relative Expression (log2-ratio):-5.254469
Number of Samples:3 / 5
Experimental necrotizing myopathy study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).